Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

174.95USD
3:59pm EST
Change (% chg)

$-1.74 (-0.98%)
Prev Close
$176.69
Open
$175.25
Day's High
$176.56
Day's Low
$174.78
Volume
589,159
Avg. Vol
420,840
52-wk High
$182.46
52-wk Low
$123.73

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $46,023.13
Shares Outstanding(Mil.): 302.84
Dividend: 0.15
Yield (%): 0.61

Financials

  SHPG.OQ Industry Sector
P/E (TTM): 66.53 31.13 34.39
EPS (TTM): 2.27 -- --
ROI: 1.15 15.55 14.96
ROE: 2.31 16.92 16.52

UPDATE 4-Takeda clears key hurdle as investors back $59 billion Shire deal

* Shares in Shire and Takeda both gain ground (Updates with approval from Shire shareholders)

Dec 05 2018

Takeda shareholders approve Shire acquisition - spokesman

TOKYO, Dec 5 Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, a Takeda spokesman said, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.

Dec 04 2018

EU mergers and takeovers (Nov 20)

BRUSSELS, Nov 20 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Nov 20 2018

EU approves Takeda buying Shire, on divestment condition

BRUSSELS The European Commission said on Tuesday that it approved the $62-billion takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.

Nov 20 2018

EU approves Takeda buying Shire, on divestment condition

BRUSSELS, Nov 20 The European Commission said on Tuesday that it approved the $62-billion takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.

Nov 20 2018

Investor advisory firms back Takeda's $62 billion deal for Shire

LONDON Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.

Nov 20 2018

Investor advisory firms back Takeda's $62 billion deal for Shire

LONDON, Nov 20 Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion takeover offer for drugmaker Shire, dealing a blow to a group of investors who hope to block the deal.

Nov 20 2018

EU mergers and takeovers (Nov 16)

BRUSSELS, Nov 16 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Nov 16 2018

UK Stocks-Factors to watch on Nov 13

Nov 13 Britain's FTSE 100 index is seen opening 15 points higher at 7,068 on Tuesday, according to financial bookmakers. * SHIRE, TAKEDA: Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire, according to documents for the deal published on Monday. * IQE: British chipmaker IQE Plc warned on Monday that its current-year financial results would be lower, after fellow Apple sup

Nov 13 2018

Takeda's Shire takeover to bring $963 million fee bonanza

LONDON Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire , according to documents for the deal published on Monday.

Nov 12 2018

Earnings vs. Estimates